

1 **The Place of Fluvoxamine in the Treatment of Non-critically ill Patients with**
2 **COVID-19: A Living Systematic Review and Meta-analysis**

3
4 Salah Eddine Oussama Kacimi^{1,2*+}, Elona Greca^{1,3+}, Mohamed Amine Haireche⁴, Ahmed Sallam
5 ElHawary⁵, Mounir Ould Setti⁶, Rebecca Caruana⁷, Sahar Rizwan⁸, Hidayet Benyettou^{1,9},
6 Mohammad Yasir Essar¹⁰, Jaffer Shah^{11,12} & Sherief Ghozy¹³

7
8
9 ¹ Division of Research and Academic Affairs, Larkin Community Hospital, South Miami, USA

10 ² Faculty of Medicine, University of Tlemcen, Tlemcen, Algeria

11 ³ University of Medicine, Tirana, Albania

12 ⁴ Building 6822, Waly al Ahd, Holy Makkah 4024-24353, KSA

13 ⁵ Qena Faculty of Medicine, South Valley University, Qena, Egypt.

14 ⁶ Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio,
15 Finland

16 ⁷ Faculty of Medicine and Surgery, University of Malta, Malta

17 ⁸ Jinnah Sindh Medical University, Karachi, Pakistan

18 ⁹ Department of Cardiology, University-Hospital Center of Tlemcen, Tlemcen, Algeria

19 ¹⁰ Kabul University of Medical Sciences, Kanya, Afghanistan

20 ¹¹ Medical Research Center, Kateb University, Kabul, Afghanistan

21 ¹² Drexel University College of Medicine, Philadelphia, PA, US

22 ¹³ Department of Radiology, Mayo Clinic, Rochester, MN, US

23 ⁺ Co-first authors

24 ^{*} Correspondence

25
26 **Corresponding authors:** Salah Eddine Oussama Kacimi; Faculty of Medicine, University of
27 Tlemcen, Tlemcen 13000, Algeria; Kacimi.oussama97@yahoo.com; +213 557106895.

28

29

30

31

32

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33

34

35

36

37

38

39

40 Abstract

41

42 **Background:** Fluvoxamine is a selective serotonin reuptake inhibitor that is known to be used as
43 antidepressant. Repurposing of Fluvoxamine for the treatment of COVID-19 is theorized to help
44 in the prevention of the clinical deterioration of SARS CoV-2 patients. In our systematic review
45 and meta-analysis, we aim to assess the safety and efficacy of the drug under study in terms of its
46 effect on the mortality and the risk of hospitalization and mechanical ventilation in non-critically
47 ill COVID-19 patients.

48

49 **Methods:** We performed a systematic search of seven electronic databases. The search results
50 were screened based on the previously determined inclusion and exclusion criteria. We
51 determined the data related to our objectives. The mortality rates, rates of hospitalization, risk of
52 mechanical ventilation and serious side effects were extracted from the studies that successfully
53 met our inclusion and exclusion criteria. Then, the extracted data from the included studies was
54 included in the meta-analysis.

55

56 **Results:** Three studies, two randomized clinical trials and one observational cohort study, with
57 1762 patients, were the final outcome of our search and screening processes. Among all
58 participants, 886 patients received Fluvoxamine while 876 were controls. Follow up periods
59 ranged from 7 days to 28 days. There was no significant difference in the intention-to-treat
60 mortality rates between the two groups (RR = 0.66; 95% CI: 0.36 - 1.21, p-value = 0.18; I^2 =
61 0%). However, Fluvoxamine decreased the per-protocol mortality compared to both placebo
62 alone or placebo/standard care (RR = 0.09; 95% CI: 0.01 - 0.64, p-value = 0.02; I^2 = 0% and RR
63 = 0.09; 95% CI: 0.01 - 0.72, respectively). As compared to placebo or standard care, the all-
64 cause hospitalization was significantly reduced in the fluvoxamine group (RR = 0.71; 95% CI:
65 0.54 - 0.93, p-value = 0.01; I^2 = 61%). This risk reduction was not significant when compared to
66 placebo alone (RR = 0.76; 95% CI: 0.57 - 1.00; p-value = 0.051; I^2 = 48%). Furthermore, the risk
67 of mechanical ventilation was not improved in the fluvoxamine group as compared to placebo
68 (RR = 0.71; 95% CI: 0.43 - 1.16, p-value = 0.17; I^2 = 0%). The serious adverse effects were
69 almost the same in the treatment group and the control (13% and 12% respectively).

70

71 **Conclusion:** Fluvoxamine does not significantly reduce the mortality rates or the risk of
72 mechanical ventilation in SARS CoV-2 patients. Nonetheless, it was found to have a good
73 impact on reducing all cause hospitalization among patients with COVID-19 disease. Therefore,
74 further clinical studies are needed to determine the effectiveness of the drug and its mechanisms
75 of action.

76

77

78

79

80

81 **Introduction**

82

83 Coronavirus disease 2019 (COVID-19) is a pandemic that has emerged in the city of Wuhan,
84 China, at the end of 2019 and has spread with highly transmissibility all over the globe in
85 2020^{[1],[2],[3]}. Symptoms severity, according to the largest cohort of more than 44,000 persons
86 infected with COVID-19 from China, can range from mild (81%), severe (14%) to critical (5%)
87 ^{[4],[5]}. During the critical phase, patients may rapidly deteriorate one week after coronavirus
88 disease onset, which increases the urge to discover drugs that prevents this condition ^{[6],[7]}.

89 In November 2020, a randomized clinical trial, reported by Dr. Lenze and his colleagues
90 assessed the efficacy of Fluvoxamine (FLV) in adult patients with COVID-19 for prevention of
91 clinical deterioration ^[8]. FLV is a selective serotonin reuptake inhibitor (SSRI), mainly used to
92 treat obsessive-compulsive disorder, but also major depressive disorder and anxiety disorders^[9].
93 It has not been FDA-approved for the treatment of any infection since April 2021 when it was
94 added to the US National Institutes of Health (NIH) COVID-19 Guidelines Panel ^[10].

95 Potential mechanisms of action of FLV for COVID-19 are the immune modulation aspect and
96 antiviral effect ^[11,12,13]. There are four factors that might play a key role in immune modulation.
97 First, the activity of the sigma 1 receptor that could be leading to inositol-requiring enzyme
98 1alpha - driven (IRE1). Second, the decreased activity of platelet aggregation. Third, decreased
99 activity of mast cells. Fourth, increased level of melatonin by cytochrome P450 inhibition. All of
100 them play a significant role in decreasing inflammation during COVID-19^[11,12,14]. On the other
101 hand, the anti-viral effect of FLV is focused on the interference with viral entry and
102 endolysosomal viral trafficking ^[11].

103 We aimed to carry out a systematic literature review and meta-analysis of all published RCTs
104 and prospective cohort studies to evaluate the safety and efficacy of Fluvoxamine in non-
105 critically ill patients with confirmed COVID-19 diagnosis, with the goal of helping to clarify the
106 possibility of repurposing of this drug.

107

108

109

110

111

112

113

114

115 **Methods**

116

117 **Data Source**

118

119 We followed the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-
120 Analyses) checklist for reporting systematic reviews and meta-analyses ^[15]. One investigator
121 systematically searched Medline, Google Scholar, Scopus, OpenGrey, Clinicaltrials.gov,
122 Cochrane, and MedRxiv from database inception till November 1st, 2021 to retrieve studies in
123 humans of the efficacy and safety of Fluvoxamine in the treatment of non-critically ill patients
124 with confirmed COVID-19 diagnosis. The following keywords were used for the retrieval of
125 relevant studies: “*Fluvoxamine*”, “*COVID*”, “*COVID-19*”, and “*Coronavirus*”. Additionally,
126 the reference list of the included studies was scrutinized to retrieve further studies. Finally, we
127 included all original studies with no publication date or language restrictions to not miss any
128 relevant papers.

129

130 **Study Selection**

131

132 Studies were considered relevant if 1) their aim was to assess the efficacy and/or safety of
133 Fluvoxamine in the treatment of non-severe cases of COVID-19 2) they are double-arm studies
134 3) patients in these studies diagnosed with COVID-19 or its symptomatology is not severe
135 enough to require hospitalization at baseline 4) reported enough data to be used in the meta-
136 analysis. Therefore, we included both observational studies (cohort studies) and clinical trials.
137 Studies conducted among ICU-admitted patients were not considered in this meta-analysis. If a
138 specific dataset has been published more than once, we used the most recent publication.
139 Preprints without peer-reviewed publication were also included. We excluded studies that were
140 not reported as full reports such as conference abstracts and letters unless they provide enough
141 data. Secondary studies including systematic reviews, narrative reviews, and computational
142 studies were excluded from this systematic review. Studies performed on animal models were
143 also excluded.

144

145 **Data Extraction & Quality Assessment**

146

147 The following data were extracted by two independent reviewers from each article: country,
148 study design, number of participants in both Fluvoxamine and control arms, Fluvoxamine dose,
149 and drug-intake duration, duration of the follow-up, percentage of participants lost in follow-up,
150 and description of the reported primary outcomes. Additionally, demographic data of studies’
151 participants were also extracted. Separately, the outcomes reported in the studies including
152 intention-to-treat mortality, per-protocol mortality, mechanical ventilation, hospitalization,
153 presence of serious adverse events (SAE), and presence of any adverse events (AE) were
154 extracted as raw data (event and total) and not as effect estimates. Grade 3, 4, and 5 adverse
155 events reported by the TOGETHER study ^[16] were considered as SAEs. The quality of the

156 included studies was assessed by two other independent reviewers using the NIH Quality
157 Assessment Tool for Controlled Intervention Studies and Cohort Studies [17].

158

159 **Data Synthesis & Analysis**

160

161 The primary endpoint was to assess the effect of Fluvoxamine on the risk of mortality,
162 mechanical ventilation, or hospitalization among COVID-19 patients without severe illness at
163 baseline. In the first part, we gathered raw data represented by the number of event occurrences
164 among total patients in each arm from both observational and interventional studies. Thereafter,
165 we calculated pooled effect estimates and their corresponding 95% confidence intervals (CI)
166 from these raw data. At the second time, only interventional studies comparing Fluvoxamine
167 with placebo were considered in separate meta-analyses. Because of the prospective nature of all
168 the included studies, Relative Risk (RR) was used as an effect estimate.

169

170 All data were analyzed by means of the “meta” package; R software version 4.0.2. We computed
171 the pooled RRs and their corresponding 95% CI using the fixed effects model. Heterogeneity of
172 the effect across studies was assessed by Q^2 statistics, which is distributed as X^2 statistics [18]. A
173 value of p-value < 0.05 was used to indicate a lack of homogeneity (heterogeneity) among
174 effects. I^2 statistics were provided to quantify the percentage of total variation across studies that
175 was attributable to heterogeneity rather than to chance. We used a fixed-effects model if the I^2 p-
176 value significance was < 0.05. Otherwise, a random-effects model was used. Due to the small
177 number of the included studies (<10 per the analysis), neither subgroup analysis, Egger’s
178 regression test for the assessment of publication bias nor meta-regression were possible [19,20].

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198 **Results**

199

200 **Inclusion flowchart**

201

202 Two independent reviewers screened the title and abstracts of 155 potentially relevant non-
203 duplicate studies. Of the 155 abstracts, a total of 96 abstracts was excluded due to the reasons
204 mentioned in the PRISMA flow diagram (**Figure 01**). Consequently, full texts of 11 studies were
205 assessed for eligibility of which 8 were excluded (7 studies did not meet the first eligibility
206 criteria and 1 study was reported among patients admitted to the ICU ^[21]. Additionally, no
207 studies were identified through hand-searching of the reference list of the included studies.
208 Finally, three studies (2 interventional and 1 observational) met the eligibility criteria and were
209 included in the review and meta-analysis. The PRISMA flow diagram is depicted in (**Figure 01**)

210

211 **Description of the included studies**

212

213 All included studies were published in English. Among the three studies, two ^[16,8] were
214 randomized double-blinded placebo-controlled trials and one ^[22] was an observational cohort
215 study. All the included studies were prospective with a maximum follow-up duration of 28 days
216 reported in the TOGETHER study. The minimum follow-up duration was 14 days. The sample
217 size of the included studies ranged from 133 to 1497. Two studies were conducted in the United
218 State of America and one study in Brazil. Fluvoxamine was administered daily at different doses
219 and durations in the included studies. Primary outcomes were heterogeneous among included
220 studies. COVID OUT study assessed the clinical deterioration of COVID-19 patients,
221 TOGETHER study assessed the retention in COVID-19 emergency or transfer to tertiary care,
222 while Seftel et al. assessed mortality, ICU admission, and persistence of COVID-19
223 symptomatology as the primary outcome. Details of the characteristics of the included studies
224 can be found in (**Table1**)

225

226 **Baseline characteristics of studies' participants**

227

228 All the included studies reported age, percentage of gender, ethnicity/race, and comorbidities.
229 However, Seftel et al. failed to provide data regarding body-mass index (BMI). Additionally,
230 Seftel et al. reported data on only three comorbidities (hypertension, diabetes, and chronic lung
231 disease). Baseline characteristics were not different between Fluvoxamine arm and control arm
232 among the included studies except for gender that was not well-matched in Seftel et al. with 59%
233 of males in Fluvoxamine arm and 41% in standard care arm. Diabetes, hypertension, and lung
234 disease are the most prevalent comorbidities among participants. Full demographic data can be
235 found in (**Table2**)

236

237 **Outcomes**

238

239 *Fluvoxamine compared to placebo or standard care (observation)*

240

241 Fluvoxamine did not reduce risk of mortality from COVID-19 RR = 0.66 (95% CI: 0.36 - 1.21,
242 p-value = 0.18; $I^2 = 0\%$). However, when we used the per protocol mortality data of
243 TOGETHER study, Fluvoxamine has significant reduction in per protocol mortality as compared
244 to the placebo or standard care (SC) RR = 0.09 (95% CI: 0.01 - 0.64, p-value = 0.02; $I^2 = 0\%$).
245 As compared to placebo or SC, Fluvoxamine showed benefit on reducing risk for all-cause
246 hospitalization RR = 0.71 (95% CI: 0.54 - 0.93, p-value = 0.01; $I^2 = 61\%$), but did not for the
247 risk of mechanical ventilation (MV) RR = 0.71 (95% CI: 0.43 - 1.16, p-value = 0.17; $I^2 = 0\%$).
248 Forest plots can be found on the (**Supplementary**).

249

250 *Fluvoxamine compared to a placebo alone*

251

252 When compared to placebo alone, Fluvoxamine did no reduce the risk of intention-to-treat death
253 RR = 0.69 (95% CI: 0.38 - 1.27, p-value = 0.24), but showed a benefit on per protocol death RR
254 = 0.09 (95% CI: 0.01 - 0.72, p-value = 0.02). When compared to placebo alone, Fluvoxamine did
255 not reduce the risk for both MV and hospitalization RR = 0.76 (0.46 - 1.24, p-value = 0.27; $I^2 =$
256 0%) and RR = 0.76 (0.57 - 1.00, p-value = 0.051; $I^2 = 48\%$), respectively. Incidence of serious
257 adverse events was not different among Fluvoxamine (10%) and placebo arm (12%) (p-value for
258 RR = 0.09). Similarly, the incidence of any other adverse events was almost identical between
259 treatment group (13%) and placebo group (12%) RR = 1.06 (0.82 - 1.38, p-value = 0.65; $I^2 =$
260 0%). Details regarding outcomes can be found on (**Table3**)

261

262 **Risk of bias**

263

264 Using the NIH quality assessment tool for interventional studies, we find both RCTs to be of
265 good quality. On the other hand, the quality of the prospective cohort study by Seftal et al. was
266 fair using the same tool adapted for cohort studies.

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281 **Discussion**

282

283 COVID-19 disease is the disease of the era. Its high prevalence forced the Scientists to race
284 against time to find a vaccine that prevents infection, as well as a treatment for the severe
285 symptoms of the disease. Many theoretical experiments have suggested the repurposing of
286 particular drugs, and accordingly, many clinical studies have been conducted to verify the
287 effectiveness of these proposed drugs [23,24]. Some of these medicines have proven effective,
288 whether in relieving the symptoms or even in curing the disease. Fluvoxamine was one of these
289 drugs [10]. It is a drug for the nervous system used as an antidepressant through its action as a
290 selective serotonin reuptake inhibitor (SSRI) [25]. The use of antidepressant drugs as antiviral
291 agents was not of the moment. They have previously been used in the Middle East Respiratory
292 Syndrome (MERS) and the Severe Acute Respiratory Syndrome (SARS), and some clinical and
293 preclinical studies have proven their success in improving the condition of patients with these
294 two diseases [26,27].

295 Repurposing of fluvoxamine was theorized to be beneficial in preventing the progression of
296 severity of SARS CoV-2 disease [8]. These theories were based on the anti-inflammatory
297 properties of the drug which come mainly from its moderate to high affinity to sigma-1 receptors
298 (S1R) [28]. Among all antidepressants, fluvoxamine was found to have the highest potency at S1R
299 [29-31]. S1R is an endoplasmic reticulum (ER) chaperone protein that plays a regulatory role of
300 cytokines production in the settings of inflammation [30]. It interferes with the ER stress (cytokine
301 storm) syndrome which occurs accordingly to the SARS CoV-2 viral replication within the
302 human cells and contributes to the high mortality of the disease [30,32-33]. In addition, S1R was
303 identified by Gordon et al to play a pivotal inhibitory role in the viral RNA replication process of
304 SARS CoV-2 [30,34]. Thus, the agonistic effect of fluvoxamine on sigma-1 receptors has
305 supported the theories of its use as anti-inflammatory and antiviral agent in the treatment of
306 SARS CoV-2 disease [29]. There are many other theories (e.g. inhibition of platelet aggregation,
307 mast cell degranulation and lysosomotropism) linking the mechanisms of action of fluvoxamine
308 and its possible efficacy in COVID-19 patients [11].

309 A few clinical studies have been conducted to confirm the efficacy of fluvoxamine in alleviating
310 the severe symptoms and preventing the progression of the disease. In our systematic review and
311 meta-analysis, we assessed the efficacy of fluvoxamine in terms of its effects on mortality rates,
312 risk of hospitalization and mechanical ventilation as factors that can be relied upon to determine
313 the effectiveness of the drug in treating the disease.

314 Although the COVID OUT randomized clinical trial (which was performed by Lenze et al [8])
315 was not a large trial, it opened the gaze for the high need to perform larger trials to reach a
316 reliable conclusion about the efficacy of the drug. Of all the included studies, the TOGETHER
317 trial was the largest and the most recent trial [16].

318 The increased mortality rates among COVID 19 patients increased the demand to check for
319 drugs that may reduce the high risk of death especially in advanced age [35, 36]. In their large
320 multicenter retrospective observational cohort study, Oskotsky et al indicated the effectiveness of
321 SSRIs, specifically fluoxetine and fluoxetine or fluvoxamine, in reducing the mortality rates
322 among the groups that used this category of antidepressants compared to the control group [37]. In
323 our review, we found that there was no significant difference in the ITT mortality rates between
324 fluvoxamine group and placebo or SC (RR = 0.66; 95% CI: 0.36 - 1.21). However, the PP
325 mortality from the TOGETHER trial indicated a real and effective difference between the two
326 groups (RR = 0.09; 95% CI: 0.01 - 0.64). Therefore, this can give the preference to the use of
327 fluoxetine over fluvoxamine in the reduction of mortality among COVID-19 patients. We can
328 also infer from this the superiority of fluoxetine and fluvoxamine over the other SSRIs [37, 38].

329 **Conclusion**

330

331 Repurposing of fluvoxamine in treatment of SARS CoV-2 patients has not shown significant
332 efficacy in reducing either the mortality rates or mechanical ventilation. However, it showed
333 promising results in reducing the risk for hospitalization among patients with COVID-19 disease.
334 There is still an urgent need for more clinical studies to determine the extent of its effectiveness
335 and to know more about its biological mechanisms in COVID-19 patients.

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350 **References**

351

352 1. World Health Organization. Corona- virus disease (COVID-19) outbreak. Available at
353 <https://www.who.int/health-topics/coronavirus>. last accessed in 5th of November 2021.

354 2. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in wuhan China:
355 the mystery and the miracle. *J Med Virol*: published online Jan 16. DOI:10.1002/jmv.25678.

356 3. Hui, D. S. et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global
357 health - the latest 2019 novel coronavirus outbreak in Wuhan, China. *Intl. J. Infect. Dis.* 91, 264–
358 266 (2020).

359 4. Liu Y, Yan L, Wan L, Xiang T, Le A, Liu J et al. Viral dynamics in mild and severe cases of
360 COVID-19. *The Lancet Infectious Diseases*. 2020;20(6):656-657.

361 5. Zhonghua Liu Xing Bing Xue Za Zhi. Epidemiology Working Group for NCIP Epidemic
362 Response, Chinese Center for Disease Control and Prevention. The epidemiological
363 characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. 2020;
364 41:145–151.

365 6. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-
366 CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet*
367 *Respir Med* 2020

368 7. Sheng-long Chen, et al. Patterns of Deterioration in Moderate Patients With COVID-19 From
369 Jan 2020 to Mar 2020: A Multi-Center, Retrospective Cohort Study in China. *Front. Med.*, 03
370 December 2020 | <https://doi.org/10.3389/fmed.2020.567296>

371 8. Lenze E, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L,
372 Yingling M, Avidan MS, Reiersen AM. Fluvoxamine vs placebo and clinical deterioration in
373 outpatients with symptomatic COVID-19. A randomized clinical trial. *JAMA*.
374 2020;324(22):2292–2300. doi: 10.1001/jama.2020.22760.

375

376 9. Figgitt, D.P., McClellan, K.J. Fluvoxamine. *Drugs* **60**, 925–954 (2000).
377 <https://doi.org/10.2165/00003495-200060040-00006>

378 10. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment
379 Guidelines. National Institutes of Health. Available at
380 <https://www.covid19treatmentguidelines.nih.gov/>. Accessed [5th of November 2021].

381 11. Sukhatme VP, Reiersen AM, Vayttaden SJ and Sukhatme VV (2021) Fluvoxamine: A
382 Review of Its Mechanism of Action and Its Role in COVID-19. *Front. Pharmacol.* 12:652688.
383 doi: 10.3389/fphar.2021.652688

384

385 12. Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric
386 diseases and its clinical implication. *Journal of Pharmacological Sciences*. 2015;127(1):6-9.

387

388 13. Hashimoto, K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-
389 1 receptor. *Eur Arch Psychiatry Clin Neurosci* **271**, 249–258 (2021).

390 <https://doi.org/10.1007/s00406-020-01231-x>

391

392 14. DeDiego M, Nieto-Torres J, Jiménez-Guardeño J, Regla-Nava J, Álvarez E, Oliveros J et al.
393 Severe Acute Respiratory Syndrome Coronavirus Envelope Protein Regulates Cell Stress
394 Response and Apoptosis. *PLoS Pathogens*. 2011;7(10):e1002315.

395

396 15. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred Reporting Items for Systematic
397 Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Medicine*. 2009;6(7):e1000097.

398

399 16. Reis G, dos Santos Moreira-Silva E, Silva D, Thabane L, Milagres A, Ferreira T et al. Effect
400 of early treatment with fluvoxamine on risk of emergency care and hospitalisation among
401 patients with COVID-19: the TOGETHER randomised, platform clinical trial. *The Lancet*
402 *Global Health*. 2021;10(1):e42-e51.

403

404 17. NIH Quality Assessment Tools. [https://www.nhlbi.nih.gov/health-topics/study-quality-](https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools)
405 [assessment-tools](https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools) last accessed in 17 December 2021.

406

407 18. Higgins JPT, Green S. Identifying and measuring heterogeneity. In: Julian PTH, Sally G,
408 editors. *Cochrane Handbook for Systematic Reviews of Interventions*. Chichester: Co-
409 *Publication Between The Cochrane Collaboration*; (2011)

410

411 19. Egger M, Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple,
412 graphical test. *BMJ*. 1997;315(7109):629-634.

413

414 20. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. *Comparison* of two methods to
415 detect publication bias in meta-analysis. *JAMA*. 2006 Feb 8; 295(6):676-80.

416

417 21. Calusic M, Marcec R, Luksa L, Jurkovic I, Kovac N, Mihaljevic S, Likic R. Safety and
418 efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with
419 matched controls. *Br J Clin Pharmacol*. 2021 Nov 1;10.1111/bcp.15126. doi: 10.1111/bcp.15126.
420 Epub ahead of print. PMID: 34719789; PMCID: PMC8653355.

421

422 22. Seftel D, Boulware DR. Prospective Cohort of Fluvoxamine for Early Treatment of
423 Coronavirus Disease 19. *Open Forum Infect Dis*. 2021 Feb 1;8(2): ofab050. doi:
424 10.1093/ofid/ofab050. PMID: 33623808; PMCID: PMC7888564.

- 425
- 426 23. Yousefi, Hassan et al. "Repurposing existing drugs for the treatment of COVID-19/SARS-
- 427 CoV-2 infection: A review describing drug mechanisms of action." *Biochemical pharmacology*
- 428 vol. 183 (2021): 114296. doi: 10.1016/j.bcp.2020.114296.
- 429
- 430 24. Farne, Hugo et al. "Repurposing Existing Drugs for the Treatment of COVID-19." *Annals of*
- 431 *the American Thoracic Society* vol. 17,10 (2020): 1186-1194. doi:10.1513/AnnalsATS.202005-
- 432 566FR
- 433 25. Burton, S W. "A review of fluvoxamine and its uses in depression." *International clinical*
- 434 *psychopharmacology* vol. 6 Suppl 3 (1991): 1-17; discussion 17-21. doi:10.1097/00004850-
- 435 199112003-00001.
- 436 26. Cao, Jianzhong, J. Craig Forrest, and Xuming Zhang. "A screen of the NIH Clinical
- 437 Collection small molecule library identifies potential anti-coronavirus drugs." *Antiviral research*
- 438 114 (2015): 1-10.
- 439 27. Dyall, Julie, et al. "Repurposing of clinically developed drugs for treatment of Middle East
- 440 respiratory syndrome coronavirus infection." *Antimicrobial agents and chemotherapy* 58.8
- 441 (2014): 4885-4893.
- 442 28. Rosen, Dorian A et al. "Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in
- 443 preclinical models of inflammation and sepsis." *Science translational medicine* vol. 11,478
- 444 (2019): eaau5266. doi:10.1126/scitranslmed.aau5266.
- 445 29. Ishima, Tamaki et al. "Interaction of new antidepressants with sigma-1 receptor chaperones
- 446 and their potentiation of neurite outgrowth in PC12 cells." *European journal of pharmacology*
- 447 vol. 727 (2014): 167-73. doi: 10.1016/j.ejphar.2014.01.064.
- 448 30. Hashimoto, Kenji. "Repurposing of CNS drugs to treat COVID-19 infection: targeting the
- 449 sigma-1 receptor." *European archives of psychiatry and clinical neuroscience* vol. 271,2 (2021):
- 450 249-258. doi:10.1007/s00406-020-01231-x.
- 451 31. Hashimoto, Kenji. "Activation of sigma-1 receptor chaperone in the treatment of
- 452 neuropsychiatric diseases and its clinical implication." *Journal of pharmacological sciences* vol.
- 453 127,1 (2015): 6-9. doi: 10.1016/j.jphs.2014.11.010.
- 454 32. "Fluvoxamine for COVID-19?" *The Medical letter on drugs and therapeutics* vol. 63,1623
- 455 (2021): 69-70
- 456 33. Banerjee, Aditi et al. "Crosstalk between endoplasmic reticulum stress and anti-viral
- 457 activities: A novel therapeutic target for COVID-19." *Life sciences* vol. 255 (2020) : 117842.
- 458 Doi : 10.1016/j.lfs.2020.117842.
- 459 34. Gordon, David E et al. "A SARS-CoV-2 protein interaction map reveals targets for drug
- 460 repurposing." *Nature* vol. 583,7816 (2020): 459-468. doi:10.1038/s41586-020-2286-9

461 35. Challen, Robert, et al. "Risk of mortality in patients infected with SARS-CoV-2 variant of
462 concern 202012/1: matched cohort study." *bmj* 372 (2021).

463 36. CDC, COVID 19 updates. [https://www.cdc.gov/coronavirus/2019-ncov/covid-
data/investigations-discovery/hospitalization-death-by-age.html](https://www.cdc.gov/coronavirus/2019-ncov/covid-
464 data/investigations-discovery/hospitalization-death-by-age.html). last accessed on 12 Dec. 2021.

465 37. Oskotsky, Tomiko et al. "Mortality Risk Among Patients With COVID-19 Prescribed
466 Selective Serotonin Reuptake Inhibitor Antidepressants." *JAMA network open* vol. 4,11
467 e2133090. 1 Nov. 2021, doi:10.1001/jamanetworkopen.2021.33090.

468

469 38. Hoertel, Nicolas. "Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine
470 and Fluvoxamine Reduce Mortality Among Patients With COVID-19?" *JAMA network open*
471 vol. 4,11 e2136510. 1 Nov. 2021, doi:10.1001/jamanetworkopen.2021.36510.

472

473 **Table 01:** Characteristics of the included studies.

474 **Table 02:** Baseline characteristics among patients of the included studies.

475 **Table 03:** Summary of the patients' outcomes.

476 **Figure 01:** PRISMA flow chart of the systematic review.

477

478

479

480

481

482

483

484

485

486

487

488

489

490

Study	Country	Study design	Population, N		Fluvoxamine dose/ duration	FU duration	Loss of FU, %	Primary outcome
			Fluv	Control				
COVID OUT	USA	Double-blinded Placebo-controlled RCT	80	72	100mg x 3/ 15 days	15 days	20%	clinical deterioration
TOGETHER	Brazil	Double-blinded Placebo-controlled RCT	741	756	100mg x 2/ 10 days	28 days	NA	retention in a COVID-19 emergency setting/transfer to the tertiary hospital due to COVID-19
Seftel et al. 2021	USA	Observational prospective cohort study	65	48	50mg x 2/ 14 days	14 days	0%	Hospitalization, ICU admission mortality, the persistence of symptoms

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

Table 2: Baseline characteristics among patients of the included studies

Baseline Characteristics	TOGETHER		COVID OUT		Seftel et al. 2021	
	Fluvoxamine (N = 741)	Placebo (N = 756)	Fluvoxamine (n = 80)	Placebo (n = 72)	Fluvoxamine (n = 65)	Standard care (n = 48)
Age, Median (IQR)	50 (39–56)	49 (38–56)	46 (35-58)	45 (36-54)	44 ± 15 ^a	43 ± 15 ^a
Males, %	45	40	30	26	59	41
Race, %						
Black or African American	1	1	23	28	1.5	0
Mixed race	96	95	-	-	-	-
White	1	1	70	69	5	27
Unknown	3	3	1	0	-	-
Ethnicity, %						
Asian	-	-	4	1	0	2
Latino	-	-	4	3	94	71
Chronic comorbidity, %						
Anxiety	-	-	6	1	-	-
Asthma	2	2	21	13	-	-
Auto-immune diseases	0	< 1	-	-	-	-
Chronic heart disease	1	1	-	-	-	-
Chronic kidney disease	< 1	< 1	-	-	-	-
Chronic neurological disease	1	1	-	-	-	-
Chronic pulmonary disease	1	< 1	-	-	3	2
Depression	-	-	1	6	-	-
Diabetes	17	15	11	11	17	8
Hyperlipidemia	-	-	9	10	-	-
Hypertension	14	12	19	21	17	35
Rheumatological disorder	< 1	0	5	4	-	-
Any other disease	3	3	-	-	-	-
Body-mass index, %						
<30 kg/m ²	48	49	46	42	-	-
≥30 kg/m ²	51	50	54	58	-	-
Unspecified	1	1	0	0	-	-

Abbreviations: IQR, interquartile range; a, mean ± SD. All results are displayed as percentages.

510

511

512

513

514

515

516

517

518

519

Table 3: Summary of the patients' outcomes.						
Outcome	No. studies	Fluvoxamine	Control arm	Fixed-effect model		Heterogeneity
		Event/total (%)	Event/total (%)	RR (95% CI)	Test for overall effect, P-value	I², P-value
Fluvoxamine Vs. Control arm: Placebo or standard care (observation)						
Death, intention to treat	3	2%	3%	0.66 (0.36 - 1.21)	p = 0.18	0%, p = 0.53
Death, per protocol	3	0.1%	2%	0.09 (0.01 - 0.64)	p = 0.02*	0%, p = 0.62
Mechanical ventilation	3	3%	4%	0.71 (0.43 - 1.16)	p = 0.17	0%, p = 0.49
Hospitalization	3	8%	12%	0.71 (0.54 - 0.93)	p = 0.01*	61%, p = 0.08
Fluvoxamine Vs. Control arm: Placebo only						
Death, intention to treat	2	2%	3%	0.69 (0.38 - 1.27)	p = 0.24	NA
Death, per protocol	2	0.1%	2%	0.09 (0.01 - 0.72)	p = 0.02*	NA
Mechanical ventilation	2	3%	4%	0.76 (0.46 - 1.24)	p = 0.27	0%, p = 0.56
Hospitalization	2	9%	12%	0.76 (0.57 - 1.00)	p = 0.051	48%, p = 0.17
Serious adverse events ⁺	2	10%	12%	0.78 (0.59 - 1.04)	p = 0.09	48%, p = 0.17
Any other adverse events	2	13%	12%	1.06 (0.82 - 1.38)	p = 0.65	0%, p = 0.34
Abbreviations: RR: Relative Risk; *, statistical significance; +, grade (3, 4, and 5) adverse events were considered as serious.						

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

